Cambiar Aggressive Value ETF CAMX
Set alert
35.63 USD +0.47 +1.35%
At close · Nov 2
35.63 0.00 0.00%
After hours · Nov 2, 7:30 PM ET
35.63 Day range 35.63
29.89 52-week range 36.31
- YTD
- +13.07%
- 1 year
- +14.89%
- Open
- 35.63
- Prev close
- 35.15
- Mkt cap
- 67.39M
- Vol
- 59
- Avg vol
- 240
- EPS
- 1.87
- P/E
- 19.09
- Div yield
- 0.00%
More statistics
- Low
- 35.63
- High
- 35.63
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 30.21
- 200-d avg
- 29.27
3M chart
Signals (9)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 7, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 29, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| SMA: Bearish | Sep 4, 2026 | 1 month ago |
| SMA: Bullish | Sep 3, 2026 | 2 months ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 18, 2026 | 2 months ago |
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 16.69
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 30.21
- 200-day average
- 29.27
About Cambiar Aggressive Value ETF
Under normal circumstances, the fund primarily invests in equity securities of companies located in the United States. The fund typically invests in a portfolio of 20-30 issuers that Cambiar Investors, the fund’s investment adviser, believes represent the best opportunities for long-term capital appreciation. The fund is non-diversified.
News
- What Is Going On With Uber Stock on Tuesday?
- From Burritos to Bulk Groceries: Uber Scales Delivery Reach with ShopRite Partner
- Uber Axes 3,300 Jobs to Build Its Autonomous Future
- Albany Engineered Composites to Showcase Advanced Composite Solutions at CAMX 2026
- Honeywell Dumps Productivity Unit In $1.4 Billion Deal With Brady
- Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly
- Why Elevance Health Shares Are Surging Premarket On Wednesday?
- Delta Earnings Showcase 2025 Worries & Active ETF Opportunities
- CME Group Expands Nikkei Futures Offerings, Boosts Japanese Equity Derivatives
- Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients
Your note
Sign in to keep a note on CAMX — it syncs with the Stock Master app.